Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
InvestigationalHealing & recoveryIntranasalEvidence 2/5

VIP (Vasoactive Intestinal Peptide)

Also known as: Aviptadil

VIP activates VPAC1 and VPAC2 receptors, raising intracellular cyclic AMP to drive vasodilation, smooth-muscle relaxation and immune modulation.

Read full research guideBuy / compare source

This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.

Illustrative intranasal database profile for VIP (Vasoactive Intestinal Peptide)
Illustrative profileIntranasal
Database profileInvestigational
VIP (Vasoactive Intestinal Peptide)Healing & recovery
Drug class
Neuropeptide; VPAC1/VPAC2 receptor agonist
Primary targets
VPAC1, VPAC2
Dose reference
Route-dependent (investigational); e.g. inhaled aviptadil 50 mcg four times daily in studies
Half-life
~1 minute (plasma)
Developer / origin
Relief Therapeutics / NRx Pharmaceuticals (aviptadil)
Reference year
1970
Evidence score
2/5 - Weak / mixed
Evidence 2/5

Weak / mixed

VIP biology and VPAC receptor pharmacology are well characterized, but synthetic aviptadil failed its flagship COVID-19 respiratory trials and has only small or non-US-approved support elsewhere; popular intranasal use is unproven.

Mostly animal, ex vivo, cell, or indirect evidence.

Evidence basis

  • Large randomized TESICO trial of IV aviptadil for COVID-19 was negative
  • Only a small open-label sarcoidosis study showed a pulmonary signal
  • Aviptadil-phentolamine (Invicorp) approved for ED in some European countries, not US
  • Intranasal VIP for CIRS/mold illness has no published RCT

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

VIP (Vasoactive Intestinal Peptide) guides

Read the matching guide or adjacent research pages for more context.

VIP Peptide: Aviptadil, Receptors, Evidence and SafetyVIP is a short-lived signaling peptide whose synthetic form, aviptadil, has mixed clinical evidence and several unproven off-label uses.BPC-157: Strong Animal Data, Almost No Human EvidenceBPC-157 is still not an FDA-approved drug. In July 2026 an advisory committee recommended it for the 503A compounding bulks list, a non-binding step, not drug approval.BPC-157 Oral vs Injectable: What Preclinical Data Actually SupportsOral BPC-157 is marketed for convenience and gut claims; injectables dominate recovery forums. Both rest on preclinical data — not proven human route equivalence.Did the FDA Approve BPC-157? What the July 2026 Vote Actually MeansHeadlines said FDA approved BPC-157. The real story is a non-binding PCAC vote on the 503A compounding list, not NDA approval, not a sports-medicine label, not proof it works in humans.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

BPC-157

Body Protection Compound-157

2/5
Healing & recoveryResearch only

Derived from human gastric juice. Animal models suggest effects on angiogenesis, tendon healing and GI repair; human clinical data is very limited.

DetailsGuide

TB-500

Thymosin Beta-4 fragment

2/5
Healing & recoveryResearch only

Synthetic fragment of thymosin β4 studied in animal models for cell migration, angiogenesis and tissue repair. No approved human indication.

DetailsGuide
3/5
Healing & recoveryResearch only

Thymosin beta-4 sequesters monomeric G-actin to regulate the actin cytoskeleton, enabling cell migration, angiogenesis and tissue repair, with an anti-fibrotic Ac-SDKP fragment.

DetailsGuide

Category hub

Open the category page for the full comparison table and FAQ.

Healing Peptides

Compare healing peptides such as BPC-157 and TB-500 by evidence quality, mechanism, research status and practical limitations.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →